RARA(17q21)基因断裂探针

 广州健仑生物科技?有限公司 

本司长期供应尼古丁（可替宁）检测试剂盒，其主要品牌包括美国NovaBios、广州健仑、广州创仑等进口产品，国产产品，试剂盒的实验方法是胶体金方法。

我司还有很多荧光原位杂交系列检测试剂盒以及各种FISH基因探针和染色体探针等，。

RARA(17q21)基因断裂探针

   本试剂盒主要用于RARA(17q21)基因断裂的检测，里面包括即用型杂交液和DAPI复染剂。
本试剂盒仅供科研使用。

欢迎咨询

欢迎咨询

以下是我司出售的部分FISH产品：

RARA(17q21)基因断裂探针

二维码扫一扫

【公司名称】 广州健仑生物科技有限公司
【】    杨永汉 

【】
【腾讯 】
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-3室

【企业文化宣传】RARA(17q21)基因断裂探针

每逢佳节倍思亲，大家都说在“我的蛙”身上看到了自己，也看到了远在故乡牵挂着自己的家人。
 

 
春节临近，很多研究者们依然扎根在实验室忙着做实验，还没回到故乡与家人团聚。一年又一年的坚持，也许枯燥，也许辛苦，研究者们却不改初心，因为科研的目的，正是为了更好的服务于人们的健康。
 
博奥晶典科研服务提前给大家拜个早年，也请大家多多关注自己和家人的健康~
 

 
今天给大家介绍一项前列腺癌的科研成果，研究者通过系统研究，发现DNA甲基化具有作为前列腺癌非侵入式诊断标志物的潜力！
 
本研究鉴定了与前列腺癌有关的DNA甲基化位点，发现了6个候选的甲基化位点（ID：cg03052502，cg04462340，cg05163709，cg05544622，cg14466580，cg27539893），这些位点有以下特点：
1.在前列腺癌中高度特异
2.在前列腺患者尿液中检测了其中两个位点（cg05163709，cg27539893）
3.AUC-ROC分析显示cg05163709（0.915）高于经典的PSA（0.769）
4.在正常组织中保守，在肿瘤组织中变化显著
5.与年龄和地理分布无关

 
研究者找到一个甲基化位点，cg05163709与前列腺癌密切相关，支持DNA甲基化具有成为高灵敏度和特异性的诊断标志物的潜力。本研究中也对尿液中的DNA甲基化位点进行了检测，提示可以进行非侵入性的甲基化检测。
 

 
研究背景
 
用于诊断的前列腺特异抗原（PSA）检测总是产生假阳性结果，并导致不必要和/或重复活组织检查。因此迫切需要开发更灵敏更特异的诊断标志物。本研究分析了66对癌组织和相邻正常组织中的表观基因型甲基化位点，结果发现，与正常组织相比，前列腺癌组织的Y染色体上有6个异常的甲基化位点。
 
进一步使用PCa患者的尿液进行焦磷酸测序，发现一个甲基化位点（cg05163709）是潜在的生物标志物。通过ROC分析评估了这些异常甲基化位点的预测能力，发现cg05163709（0.915）的AUC高于PSA的AUC（0.769）。这些结果表明Y染色体上的cg05163709异常DNA甲基化具有成为高灵敏度和特异性的诊断标志物的潜力。
 

Whenever we think about the family, everyone says they see themselves on my frog and see their family in their hometown.

When the Spring Festival is approaching, many researchers are still working in the laboratory to do experiments and have not returned to their hometown to reunite with their families. Year after year's insistence may be boring, maybe hard, but researchers do not change their minds, because the purpose of scientific research is to better serve people's health.

Boao crystal code research service in advance for everyone a happy, also please pay more attention to the health of themselves and their families.

Today we introduce a scientific research achievement of prostate cancer. Through systematic research, researchers found that DNA methylation has potential as a noninvasive diagnostic marker for prostate cancer.

This study identified DNA methylation sites related to prostate cancer, and found 6 candidate methylation sites (ID:cg03052502, cg04462340, cg05163709, cg05544622, cg14466580, cg27539893). These loci have the following characteristics.
1. highly specific in prostate cancer
2. the two loci (cg05163709, cg27539893) were detected in the urine of the prostate patients.
The 3.AUC-ROC analysis showed that cg05163709 (0.915) was higher than the classic PSA (0.769).
4. conservative in normal tissues and significant changes in tumor tissue
5. has nothing to do with age and geographical distribution

The researchers found a methylation site. Cg05163709 is closely related to prostate cancer. DNA methylation is a potential marker for high sensitivity and specificity. In this study, the DNA methylation sites in urine were also detected, suggesting that noninvasive methylation can be detected.

Research background

The detection of prostate specific antigen (PSA) used for diagnosis always produces false positive results and leads to unnecessary and / or repeated biopsy. Therefore, it is urgent to develop more sensitive and specific diagnostic markers. In this study, 66 pairs of epigenetic methylation sites in cancer tissues and adjacent normal tissues were analyzed. It was found that there were 6 abnormal methylation sites on Y chromosome of prostate cancer tissues compared with normal tissues.

The urine of PCa patients was further sequenced by pyrophosphate, and a methylated site (cg05163709) was found to be a potential biomarker. The predictive ability of these abnormal methylation sites was evaluated by ROC analysis, and it was found that the AUC of cg05163709 (0.915) was higher than AUC (0.769) of PSA. These results suggest that the cg05163709 abnormal DNA methylation on the Y chromosome has the potential to be a highly sensitive and specific diagnostic marker.